Showing results (221-230 of 409) with videos related to

Sort By:
Pageof 41
Revista Espanola De Enfermedades Digestivas|June 1, 1995
[The incidence, prognostic factors and survival in young adults with colorectal adenocarcinoma]M Hidalgo Pascual, C Moreno Sanz, E Moreno González, et al.
Theriogenology|April 29, 2015
Effect of single-layer centrifugation or washing on frozen-thawed donkey semen quality: Do they have the same effect regardless of the quality of the sample?I Ortiz, J Dorado, J M Morrell, et al.
Biomedicines|March 25, 2022
Molecular Mechanisms Underlying the Retrieval and Extinction of Morphine Withdrawal-Associated Memories in the Basolateral Amygdala and Dentate GyrusAurelio Franco-García, Francisco José Fernández-Gómez, Victoria Gómez-Murcia, et al.
Anti-Cancer Drugs|May 18, 1999
Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assayM Hidalgo, E Izbicka, C Cerna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2003
Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activityL A DeGraffenried, W E Friedrichs, L Fulcher, et al.
Revista Espanola De Enfermedades Digestivas|December 1, 1994
[Massive pseudocysto-jejunal hemorrhage caused by rupture of pseudoaneurysm of the splenic artery]G Flati, P Negro, B Porowska, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|June 9, 2016
Assessment of the quality of cervical mucus among users of the levonorgestrel-releasing intrauterine system at different times of useLeticia G Moraes, Nadia M Marchi, Ana C Pitoli, et al.
L'Encephale|August 20, 2022
Sexual orientation, gender: Where is the problem? Nowhere! Correct self-identification and minority stigmaD Ducasse, A Alacreu-Crespo, L Lacourt, et al.
Cancer Chemotherapy and Pharmacology|September 29, 1999
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationD A Rinaldi, J G Kuhn, H A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRPE K Rowinsky, L Smith, Y M Wang, et al.
Pageof 41